There’s nothing better than getting a great value — and let’s face it, when the market tumbles, often great stocks get crushed too. That could end up being particularly true in biotech. Since 2013, the industry’s return has tripled the S&P 500’s return, and that may mean that with the market slipping lately, biotech’s leading names — including Celgene — […]
GRAND BLANC, Mich. (MarketWatch) — Much has been made of the Nasdaq Composite Index’s recent surge to the 5,000-point level, a milestone not achieved since the height of the so-called “dot-com” bubble in March 2000. At the time, venerable software titan Microsoft was the most valuable company in the composite, but its status as number one was briefly surpassed in […]
Source: Flickr user stockmonkeys.com.Investing in clinical-stage biotech stocks isn’t for the faint of heart. The industry’s jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor’s portfolio.However, for investors willing to accept the risk of buying little-known biotech stocks such as Ophthotech , Portola Pharmaceuticals , and Insys Therapeutics […]
Source: Neuralstem.I haven’t bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap companies that come with risks that are common in this highly speculative pop-and-drop industry, but for investors willing to take a risk, these […]
The Nasdaq composite remains heavily weighted toward technology, thanks to Apple’s record market valuation near $750 billion. But tech’s weighting is down sharply from the Nasdaq’s peak, while the financial, consumer services and health-care sectors have seen their weightings more than double within the composite. [See table below.]Health care’s weighting in the composite is now 16 percent, which is comparable […]
In a report published Tuesday, JMP Securities named three biotech stocks it is watching: Acceleron Pharma Inc (NASDAQ: XLRN), Cardiovascular Systems Inc (NASDAQ: CSII) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).Acceleron’s (Market Outperform, $52 price target) early stage clinical results at ASCO Genitourinary(GU) 2015 “support a positive outlook for maturing PFS results while providing encouragement for ongoing later stage development.”According to analyst Michael […]
Source: Celgene CorporationIt’s been proven time and time again that investing for the long haul outperforms short-term trading, but biotechnology stock investors must also realize that the industry moves so quickly that only the best-of-breed players ought to be stashed away for the long term. For that reason, while I’m happy to own a few speculative biotech stocks here and […]
The fact that biotech stocks can trade up or down significantly based on news from clinical research trials ensures there is no shortage of pop-and-drop stories in this business. The industry’s volatility might scare off many investors, but for those willing to accept the risk, here are three tiny biotech stocks that could make big moves thanks to the release […]
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
By iCELL News on February 20, 2015 · Investing
SummaryIn 2015, the focus of the checkpoint inhibitor space will be on additional cancer types, beyond melanoma, as well as on collaborations and combinations.
The financial resources needed to develop an advantage in the anti-PD-1/PD-L1 space are now beyond the reach of most smaller […]
This chart shows shares of Texas Instruments Inc. from Jan. 1, 2000, through today.Morningstar investment research firm has given Texas Instruments Inc. an A+ credit rating, indicating that the company is a low default risk.Related
Texas Instruments plans to boost 300mm wafer production to drive growth
Texas Instruments revenue growth returns in 2014, profits jump 30 percent
Analysts see strong 2015 semiconductor performance, […]
